N-terminal pro-brain natriuretic peptide – a promising biomarker for the diagnosis of left ventricular hypertrophy in hypertensive women  by Mouly-Bertin, Carine et al.
Archives of Cardiovascular Disease (2008) 101, 307—315
Disponib le en l igne sur www.sc iencedi rec t .com
CLINICAL RESEARCH
N-terminal pro-brain natriuretic peptide — a
promising biomarker for the diagnosis of left
ventricular hypertrophy in hypertensive women
Le peptide natriurétique de type B, fragment terminal (NT-Pro-BNP), un
marqueur prometteur pour le diagnostic d’hypertrophie ventriculaire
gauche chez les femmes hypertendues
Carine Mouly-Bertina,∗, Alvine Bisseryb,c,d,
Hugues Milonc,e, Anastase Dzudiea,
Muriel Rabilloudb,c,d, Giampiero Briccac,e,f,
Madeleine Vincentc,e,f, Pierre Lantelmea,c,e
a Service de cardiologie, hôpital de la Croix-Rousse, hospices civils de Lyon,
69317 Lyon cedex 4, France
b Service de biostatistique, hospices civils de Lyon, 69424 Lyon, France
c Université Lyon-1, 69622 Villeurbanne, France
d Laboratoire biostatistique santé, UMR 5558, CNRS, 69495 Pierre-Bénite, France
e Inserm ERI 22, 69008 Lyon, France
f Exploration fonctionnelle endocrinienne et métabolique, hôpital de la Croix-Rousse,
hospices civils de Lyon, 69004 Lyon, France
Received 6 January 2008; accepted 25 April 2008
Available online 24 June 2008
KEYWORDS
Hypertension;
Left ventricular
hypertrophy;
Summary
Introduction.— No agreement has been reached regarding the best strategy to detect left ven-
tricular hypertrophy (LVH). This study examined the role of N-terminal pro-brain natriuretic
peptide (NT-proBNP) in the diagnosis of LVH in hypertensive patients and the potential factorsNatriuretic peptide;
NT-proBNP;
that may inﬂuence its diagnostic performance.
Methods.— The global accuracy of NT-proBNP in diagnosing LVH was assessed using a receiver-
operating characteristic (ROC) curve. The inﬂuence of patients’ characteristics on test accuracy
was studied with a ROC regression based on a probit model. Ninety-three subjects were
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Sex factors;
Sensitivity and
speciﬁcity
included. All had NT-proBNP measured and underwent electrocardiography and echocardiogra-
phy, with calculation of the left ventricular mass index (LVMI).
Results.— The diagnostic performance of NT-proBNP in LVH varied slightly depending on the
indexation mode of LVMI. In cases of body surface area indexation, the area under the ROC curve
of 81.6% suggested a good performance. The accuracy of the marker was signiﬁcantly higher
in women than in men (p < 0.0001). There were no signiﬁcant effects of age, treatment, body
mass index, left ventricular mass index, 24-h systolic blood pressure, or creatinine clearance on
the test performance. Slight differences were observed when an indexation to height2.7 instead
of body surface area was used.
Conclusions.— The present results may lead to a new strategy for risk stratiﬁcation in hyper-
tension: in women, NT-proBNP alone or preferably in combination with electrocardiography
seems sufﬁcient to conﬁrm or exclude diagnosis of LVH. In men, echocardiography would only
be needed in cases of negative electrocardiography and NT-proBNP test.
© 2008 Published by Elsevier Masson SAS.
MOTS CLÉS
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Résumé
Introduction.— Il n’y a pas de consensus concernant la meilleure stratégie pour détecter une
hypertrophie ventriculaire gauche (HVG). Cette étude a évalué le rôle du NT-pro-BNP (peptide
natriurétique de type B, fragment terminal) dans le diagnostic de l’HVG chez les patients hyper-
tendus, ainsi que les facteurs potentiellement associés qui pourraient inﬂuencer la performance
diagnostique.
Méthode.— La précision globale du NT-pro-BNP dans le diagnostic d’HVG a été évaluée en
utilisant les courbes de ROC. L’inﬂuence des caractéristiques des patients sur la performance du
test a été évaluée avec une régression ROC basée sur un modèle spéciﬁque. Quatre vingt treize
sujets ont été inclus. Tous les sujets inclus avaient un NT-pro-BNP mesuré et ont bénéﬁcié d’un
électrocardiogramme, d’un échocardiogrammeavec détermination de la masse ventriculaire
gauche indexée (MVGI).
Résultats.— La performance diagnostique du NT-pro-BNP dans le diagnostic d’HVG varie en
fonction du mode d’indexation de l’indice de masse ventriculaire gauche. En cas d’indexation
à la surface corporelle, la surface sous la courbe ROC est à 81,6 %, suggérant une bonne per-
formance diagnostique. La performance de ce marqueur est signiﬁcativement plus élevée chez
les femmes que chez les hommes (p < 0,0001). Il n’y avait pas de différence signiﬁcative liée à
l’âge, au traitement, à l’indice de masse corporelle, l’index de masse ventriculaire gauche, la
pression artérielle systolique sur 24 heures ou la clairance de la créatinine sur la performance
diagnostique. Des différences mineures ont été observées lorsqu’une indexation sur la taille à
la puissance 2,7 a été utilisée et non la surface corporelle.
Conclusion.— Les résultats de cette étude pourraient conduire à une nouvelle stratégie de
stratiﬁcation du risque dans l’hypertension artérielle. Chez les femmes, le NT-pro-BNP isolé
ou l’association à l’électrocardiogramme pourraient constituer une approche sufﬁsante pour
conﬁrmer ou exclure le diagnostic d’HVG. Chez les hommes, l’échographie ne serait nécessaire
qu’en l’absence d’HVG électrique avec un NT-pro-BNP négatif.
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ntroduction
eft ventricular hypertrophy (LVH) in hypertension is a major
redictor of cardiovascular events [1,2] and therefore has
o be considered in the assessment of global cardiovascu-
ar risk [3]. In clinical practice, however, detection of LVH
s subject to various limitations. Electrocardiography (ECG),
ecommended in most guidelines, has a poor sensitivity and
s rarely performed in clinical practice [4]. Echocardiography
s also extensively used but is time-consuming, expensive,
nd not always feasible for technical reasons. Thus the
ost-effectiveness of systematic use of echocardiography in
ypertensive patients is widely debated [5].
In response to volume expansion and pressure load,
entricular myocytes release a cardiac hormone, B-type
a
o
d
nsson SAS.
atriuretic peptide (BNP), together with its N-terminal
ragment, the N-terminal pro-brain natriuretic peptide (NT-
roBNP) [6]. BNP levels are higher in hypertensive than
ormotensive patients [7]. Moreover, BNP is raised in LVH and
n diastolic dysfunction [8]. Based on these ﬁndings, BNP lev-
ls could be related to cardiac remodeling in hypertension
9,10]. Despite these interesting features, the performance
f BNP in the diagnosis of LVH is not sufﬁciently good to pro-
ose this marker for clinical use [11,12]. On the contrary,
ecause of its longer half-life and lower intra-individual vari-
bility, the biologically inactive fragment NT-proBNP may
ffer some advantages in detecting subtle preclinical car-
iac changes [13,14].
The aim of the present study was to assess the diag-
ostic value of NT-proBNP in the detection of LVH and
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factors that may inﬂuence its performance in hypertensive
patients.
Methods
Patients
One hundred and twenty-three consecutive patients
referred to our cardiology department (hôpital de la
Croix-Rousse, Lyon, France) for hypertension work-up were
considered for inclusion. Exclusion criteria were systolic
left ventricular dysfunction (shortening fraction [SF] < 25%),
atrial ﬁbrillation, and greater than mild valvular dysfunc-
tion. The study population for this analysis comprised 93
(76%) patients with a technically measurable left ventricular
mass (LVM) on echocardiography.
Study protocol
In view of a work-up for hypertension, drugs interfering with
hormonal regulations were withdrawn before hospitaliza-
tion (six weeks for spironolactone; two weeks for diuretics,
beta-blockers, and renin-angiotensin system inhibitors) and
replaced by alpha-blockers or calcium antagonists as recom-
mended [15].
Then, over a two-day hospital stay, all patients
underwent 24-h ambulatory blood pressure measurement
(ABP), ECG recording and echocardiographic assessment.
While the 24-h ABP recording was in progress, a blood
sample was taken after one night recumbence for NT-
proBNP measurement and routine biological tests. All
tests were part of the routine evaluation of hypertensive
subjects.
ABP recording
Twenty-four hour ABP recordings used Spacelabs ABP moni-
tors (Berkshire, UK), which satisfy the criteria of the British
Hypertension Society (BHS) and the Association for the
Advancement of Medical Instrumentation (AAMI) [16]. Sys-
tolic and diastolic ABP were recorded at 15-min intervals
during the day (from 7:00 to 22:00) and at 30-min intervals
during the night (from 22:00 to 7:00).
NT-proBNP measurement
Plasma concentrations of NT-proBNP were measured by an
electrochemiluminescence immunoassay using an Elecsys
2010 analyzer (Roche Diagnostics, Meylan, France). The
range of values was 5—35,000 pg/mL and the coefﬁcient of
variation was between 1 and 2.5% [17].
ECG criteria of LVHECGs were reviewed by an operator blinded to other
data (AD). LVH was deﬁned as at least one of the
following: a Sokolow index (SV1 + RV5 −V6) greater than
35mm or a Cornell voltage criterion (RVL + SV3) greater
than 28mm for men and greater than 20mm for women
[18].
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chocardiography
wo-dimensional images, M-mode, and Doppler recordings
ere obtained from a Vivid Five ultrasound device (GE
ingmed). Each parameter was recorded on three consec-
tive beats by the same experienced echocardiographist (C
-B), blinded to other data. LV dimensions were determined
rom M-mode images and were used to calculate LVM using
he Devereux formula. The intra-observer variability for LVM
alculation in our echocardiography laboratory is around 5%
19].
Two different indexations of LVM (LVMI) were used: (1)
ndexation to body surface area (LVMIBSA) according to the
uropean Society of Cardiology—European Society of Hyper-
ension (ESC-ESH) guidelines with the following LVH criteria:
MIBSA greater than 125 g/m2 in men and greater than
10 g/m2 in women [3], and indexation to height to the allo-
etric power of 2.7 (LVMI2.7) with the following LVH criteria:
VMI2.7 greater than 51 g/m2.7 in both sexes [20].
Different grades of diastolic function were deﬁned
ccording to previously published criteria [21—25] based on
itral ﬂow, pulmonary venous ﬂow, Color M-mode ﬂow prop-
gation velocity, and Doppler tissue imaging at the mitral
nnulus.
ata analysis
o assess the determinants of NT-proBNP, we used univari-
te analyses (Pearson’s coefﬁcient of correlation ‘‘r’’ and
ne-way analysis of variance) and a multivariable analysis
standard stepwise multiple linear regression). In addition
o sex, treatment, and age, the independent variables
ested in the multivariable analysis were those found sig-
iﬁcantly associated with NT-proBNP in univariate analyses.
ecause of skewed distributions, a logarithmic transforma-
ion was applied to NT-proBNP, LVMI and creatinine clearance
alues.
To estimate the global accuracy of NT-proBNP in diag-
osing LVH, an empirical receiver-operating characteristic
ROC) curve was built. The area under the ROC curve (AUC)
as estimated using the Mann—Whitney statistic and was
ompared to 50%. We used an ROC regression method [26]
o quantify the effect of patients’ characteristics on the
ccuracy of NT-proBNP. The method consisted of modelling
n indicator that can show that the NT-proBNP results in
atients with LVH are greater than speciﬁc quantiles of
he marker distribution in patients without LVH but with
he same characteristics. A generalised linear probit model
as used for this binary outcome. Because of their doc-
mented importance or their association with NT-proBNP,
e studied the effects of the following characteristics:
ge, sex, treatment, body mass index (BMI), 24-h sys-
olic ABP, creatinine clearance, LVMI (for subjects with
VH).
The Youden index [27] was used to determine a positive
hreshold for NT-proBNP, then the corresponding positive
LR+) and negative (LR−) likelihood ratios were estimated.
ost-test probabilities were calculated for a 30% estimated
revalence of LVH in primary care practice [28]. The analysis
as carried out with the statistical software Stata, version
.2. Each analysis was performed for both LVM indexations:
VMIBSA and LVMI2.7.
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Table 1 Patient characteristics (n = 93).
Characteristic Men Women All
Mean [min;max] (n = 51) Mean [min;max] (n = 42) Mean [min;max] (n = 93)
Age (years) 53.3 [20;76] 48.5 [22;75] 51.1 [20;76]
BMI (kg/m2) 28.4 [21.6;45] 26.7 [16.9;41.0] 27.6 [16.9;45]
24-h systolic ABP (mmHg) 152.1 [114;210] 149.0 [105;220] 150.7 [105;220]
24-h diastolic ABP (mmHg) 91 [65;118] 89.7 [61;125] 90.4 [61;125]
Creatinine clearance (mL/min) 100.0 [47.3;214.1] 95.8 [45.5;167.6] 98.1 [45.5;214.1]
NT-proBNP (pg/mL) 224.7 [15.5;3911] 311.5 [10;3549] 264.3 [10;3911]
LVMIBSA (g/m2) 135.1 [64.8;248.5] 113.3 [47.4;248.5] 125.2 [47.4;248.5]
Shortening fraction (%) 39.2 [27;58] 37.9 [25;54] 38.6 [25;58]
BMI: body mass index; ABP: ambulatory blood pressure; LVMIBSA: left ventricular mass indexed to the body surface area.
Results
The population comprised 42 women (45.2%) and 51 men
(54.8%). The mean 24-h systolic ABP did not differ between
sexes. Mean NT-proBNP was slightly higher in women, with a
large variation in range from 10—3911 pg/mL in both sexes
(Table 1). Overall, 76.3% of patients received the antihy-
pertensive regimen described above, with a higher rate
of treatment in men (90%) than in women (63%). Creati-
nine clearance, calculated using the Cockcroft formula, was
found to be less than 60mL/min in 4.3% of the patients; none
had a creatinine clearance below 30mL/min. The preva-
lence of LVH using the BSA indexation criterion (LVHBSA) was
44% (that is, fourfold that determined by ECG, 11%). The
prevalence of LVH using the height to the allometric power of
2.7 indexation criterion (LVH2.7) was 53%. Diastolic function
could not be estimated in 21 patients because of discrepant
indices, leaving 72 patients (77%) classiﬁed as follows: 40%
normal, 43% impaired relaxation, and 17% pseudonormal
pattern.
Determinants of NT-proBNP
In the multivariable analysis LVMIBSA, 24-h systolic ABP and
sex were independent determinants of NT-proBNP (Table 2).
Table 2 Effect of patient characteristics on NT-proBNP
level: multiple linear regression model.
Characteristic Regression
coefﬁcient
p-value
Age −0.002 0.99
Women vs men 0.26 0.04
Treatment 0.025 0.84
Log creatinine clearance −0.09 0.54
24-h systolic ABP 0.46 0.003
Log LVMIBSA 0.40 0.02
Diastolic dysfunction (1, 2,
3 for normal, moderate,
severe dysfunction)
0.07 0.69
ABP: ambulatory blood pressure; log LVMIBSA: log left ventricular
mass indexed to body surface area.
The mean NT-proBNP value was signiﬁcantly higher in women
than in men and the value increased when creatinine clear-
ance decreased. Conversely, the NT-proBNP value increased
when the 24-h systolic ABP and LVMIBSA values increased.
Similar ﬁndings were obtained for LVMI2.7.
Accuracy of NT-proBNP for diagnosing LVH
The accuracy of NT-proBNP in identifying patients with
LVHBSA (Fig. 1) was high; estimated AUC 81.6% (95% conﬁ-
dence interval 72—91). This AUC can be interpreted as the
probability that the NT-proBNP value of a patient with LVHBSA
is greater than that of a patient without LVHBSA.
The results of the ROC regression showed that the
accuracy of the NT-proBNP for the diagnosis of LVHBSA
was dependent on the patients’ characteristics (Table 3).
After adjustment for the other patients’ characteristics,
the accuracy was signiﬁcantly higher in women than in
men (p < 0.0001) and the difference between women and
men increased along with the false-positive rate (p < 0.001;
Table 3 and Fig. 2). Treatment tended to decrease the accu-
racy of the marker but the difference was not statistically
Figure 1. ROC curve of the NT-proBNP test used to identify left
ventricular hypertrophy according to body surface area indexation
(LVHBSA).
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Table 3 Effect of patient characteristics on ROC curve of NT-proBNP for diagnosis of LVHBSA: ROC regression model.
Characteristic Regression coefﬁcient 95% conﬁdence interval p-value
Women vs men 2.19 [1.05;3.34] < 0.0001
Interaction between sex and false positive rate 1.38 [0.57;2.19] < 0.001
Age 0.013 [−0.03;0.05] 0.66
BMI 0.09 [−0.01;0.19] 0.09
Creatinine clearance −0.01 [−0.03;0.003] 0.12
24-h systolic ABP 0.01 [−0.005;0.026] 0.18
LVMIBSA 0.008 [−0.003;0.02] 0.15
Antihypertensive treatment −0.8 [−1.75;0.15] 0.1
False positive rate 1.02 [0.78;1.28] < 0.0001
BMI: body mass index; ABP: ambulatory blood pressure; LVMIBSA: left ve
signiﬁcant (Table 3). With the other patients’ characteris-
tics ﬁxed to their mean (Table 1), the adjusted AUC was
estimated at 96% in treated women and 68% in treated
men (Fig. 2A) whereas it was 99% in untreated women
and 85% in untreated men (Fig. 2B). Age had no effect on
Figure 2. Adjusted ROC curves of the NT-proBNP test used to
identify left ventricular hypertrophy according to body surface area
indexation (LVHBSA), sex, and other patients’ characteristics in (A)
treated and (B) untreated men and women. Corresponding AUC
values are in brackets.
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he accuracy of the marker (Table 3). Accuracy tended to
ncrease along with increasing BMI (Fig. 3A), 24-h systolic
BP (Fig. 3B) and LVMIBSA in patients with LVHBSA, and with
he decrease in creatinine clearance (Fig. 3C). However,
he four above-mentioned effects did not reach statistical
igniﬁcance (Table 3).
When considering LVH2.7, test performance was slightly
orse, with an estimated AUC of 73.8% (95% conﬁdence
nterval 63—84). The results of the ROC regression were sim-
lar to the other indexation of LVM with a marked effect
f sex (Fig. 4). The trends observed for BMI and creatinine
learance reached statistical signiﬁcance.
The thresholds determined by the Youden index for LVHBSA
ere 111 pg/mL in men and 144 pg/mL in women, with the
orresponding performances indicated in Table 4 (the diag-
ostic performances of the retained ECG criteria are also
iven for comparison). ECG was a powerful marker of con-
rmed LVHBSA diagnosis, with 100% speciﬁcity in our study,
ut had a poor performance in excluding that diagnosis. NT-
roBNP appeared to be a more balanced test with a good
bility to conﬁrm LVHBSA in both sexes (LR+ between 7 and 8)
nd an excellent ability to exclude the diagnosis in women.
or example, in women with a pre-test probability of 30%
prevalence of LVH), the probability of LVHBSA decreased to
% when the biological test was negative versus 25% when
he ECG was negative. When electrocardiographic and bio-
ogical markers were combined, the gain in ability to exclude
VHBSA when the two tests were negative was only marginal:
R = 0.10 in women and 0.32 in men with the two markers
ersus 0.13 in women and 0.41 in men with NT-proBNP alone.
hat combination had a modest impact on the probability of
VHBSA: 4% versus 5% in women, 12% versus 15% in men, for
30% pre-test probability.
When indexation to height raised to the allometric power
f 2.7 (h2.7) was used, the Youden index was maximal for the
ame NT-proBNP value of 144 pg/mL in women. For men, it
as maximal for an NT-proBNP value of 82.4 pg/mL.
iscussionhe major ﬁndings from this study were the good per-
ormance of NT-proBNP in diagnosing LVH in hypertensive
atients, and the impact of sex on the test, with a much bet-
er diagnostic value in women than in men. These ﬁndings
312
C.
M
ouly-Bertin
et
al.
Table 4 Likelihood ratios of ECG and NT-proBNP for a threshold of 111 pg/mL in men and 144 pg/mL in women, and probability of LVHBSA according to results in a
population with a 30% prevalence of LVH.
Test Sensitivity (95%CI) Speciﬁcity (95%CI) LR+ (95%CI) Probability of LVH when
the test is positive
LR− (95%CI) Probability of LVHBSA
when test is negative
NT-proBNP
Men 0.62 (0.40;0.81) 0.93 (0.76;0.99) 8.43 (2.53;31.23) 0.78 (0.52;0.93) 0.41 (0.23;0.63) 0.15 (0.09;0.21)
Women 0.88 (0.63;0.98) 0.88 (0.69;0.97) 7.35 (2.86;21.40) 0.76 (0.55;0.9) 0.13 (0.04;0.40) 0.05 (0.02;0.15)
ECG
Men 0.25 (0.09;0.47) 1 (0.83;1) — — 0.75 (0.56;0.93) 0.24 (0.19;0.28)
Women 0.23 (0.07;0.50) 1 (0.83;1) — — 0.76 (0.54;0.96) 0.25 (0.19;0.29)
LR+: positive likelihood ratio; LR−: negative likelihood ratio.
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in detecting LVHBSA with an AUC of 81.6%, supporting the
diagnostic value of this biomarker.
Until now, few studies have evaluated natriuretic pep-
tides for the diagnosis of LVH, and most gave rather negative
results. Besides, in three studies conducted in hyperten-
sive patients, the performance of BNP alone was suboptimal
[11,12,33]. This might be due to the high intra-individual
variability [13] and short half-life [14] of this marker: two
features that impact the ability of BNP to detect subtle
cardiac variations such as those occurring in hypertension.
Indeed, NT-proBNP seems more closely related to LVH than
BNP in a study by Belluardo et al. [34]; of note, in this study
like in ours, a major effect of blood pressure on peptide
levels was disclosed. Concerning the diagnostic value of NT-
proBNP, in a study performed in a large sample from the
general population in which the prevalence of LVH was low,
the authors reported a lower diagnostic performance than
ours [35]. This may be explained by differences in the way
in which natriuretic peptides were measured, in the criteria
required to calculate LVM or by the inclusion of patients with
systolic dysfunction.
The use of a ROC regression based on a probit model
allowed us to quantify the effect of patients’ characteristics
on the accuracy of NT-proBNP. The most striking effect was
that of sex, with a signiﬁcantly higher accuracy in women
than in men, found with both LVM indexations, LVMIBSA and
LVMI2.7. This effect has not been reported so far for LVH
but is in agreement with the higher prognostic value of this
marker in women referred for acute dyspnoea [36]. A likely
explanation could be the ‘‘BNP handicap’’ evoked in men:
under testosterone inﬂuence, myocytes in men seem to pro-
duce less natriuretic peptide than those in women [37]. The
lower hypertrophic reserve in men may also contribute to
a lower release of BNP [38]. It has been speculated that
the decoupling between cardiac mass and natriuretic pep-
tide synthesis might initiate a vicious circle, leading more
rapidly to heart failure. Our results currently support the
hypothesis that early cardiac impairment, such as LVH, is
more closely related to NT-proBNP in women than in men. On
n
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he contrary, the difference in use of antihypertensive ther-
py in men and women is an unlikely explanation because
reatment did not signiﬁcantly affect the accuracy of the
est.
In accordance with previous reports [39,40], neither age
or modest renal impairment affected the performance of
he biomarker. The effect of BMI modiﬁed the capacity in
ase of h2.7 indexation but the accuracy increased along with
he increase of BMI. In the common clinical scenario of over-
eight hypertensive patients, the test could still therefore
rove useful.
Finally, the population in the present study had a rel-
tively high prevalence of LVH [41]. Interestingly, neither
ypertension severity nor LVMI level seemed to markedly
ffect the performance of NT-proBNP. All of these charac-
eristics strongly suggest that the diagnostic performance of
his marker would be the same in primary care hypertensive
atients.
One possible limitation concerns our ‘‘gold standard’’.
ndeed, although considered as the reference method,
chocardiography has a high rate of failure and a lim-
ted reproducibility. However, LVMI was measured carefully
y a single operator to avoid inter-operator variability. In
ddition, only patients with technically optimal recordings
ere included in the study to improve the accuracy of the
etermination. Finally, despite the relatively small study
opulation, the results were rather clear, especially the
ighly signiﬁcant effect of sex.
In hypertensive women, NT-proBNP alone or preferably
n combination with ECG appeared sufﬁciently efﬁcient in
onﬁrming or excluding the diagnosis of LVH without the
ecessity for further investigations. Indeed, when using
VMIBSA indexation and for a pre-test probability of 30% [28],
he negative post-test probability would decrease to 5%
ith only a marginal improvement of the test performance
y adding ECG. Similarly, the positive post-test probability
ould rise to 76% and would approach 100% by adding ECG.
his approach suggests that cardiac risk stratiﬁcation could
e based on only these two markers in hypertensive women,
ith an acceptable risk of false positives and negatives.
The picture is similar in cases of a positive test in men.
owever, in those with a negative test, the post-test prob-
bility would still be high, around 12%, which may not
e sufﬁcient to exclude the diagnosis. Thus, the optimal
pproach would be to perform an echocardiography in men
ith a negative ECG and a negative NT-proBNP test.
The combination of NT-proBNP and another diagnostic
est has already been proposed to increase the performance
f each test. For example, the combination of C-reactive
rotein (CRP) and BNP yielded a 99% negative predictive
alue, suggesting that this approach could be sufﬁcient to
xclude LVH without further investigation [33]. Two points
eserve special emphasis in our study: ﬁrst, the ECG is part
f the routine evaluation recommended in most guidelines
nd is not associated with extra costs; second, the perfor-
ance appeared much better in women than in men, which
as not tested in the aforementioned study [33].
Finally, some recent results suggest that the value of
atriuretic peptides may go beyond cardiac impairment.
cKie et al. [42] tested the predictive value of these pep-
ides in a population free of heart failure. They showed that,
ith a threshold at 109 pg/mL, a high NT-proBNP was pos-
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tively related to prognosis. A similar predictive value was
lso demonstrated by Wang et al. [43].
In our study the thresholds were determined by the
ouden index, which is a debatable choice. They may be
eﬁned according to the prevalence of LVH in the target
opulation and to the diagnostic strategy by choosing a high
ensitivity or a high speciﬁcity. However, the fact that these
hresholds were very similar to those obtained in prognos-
ic studies [42,43] strengthens their relevance and extends
heir clinical interest beyond the detection of LVH.
onclusions
ur study shows that, in addition to ECG, NT-proBNP may
rove to be a useful routine screening test for LVH in hyper-
ensive patients. This biomarker has the advantages of being
oth easy to obtain in all patients and affordable. In our
tudy, this strategy proved extremely valuable in women,
hile it may limit the need for echocardiography in men
ith a negative ECG and negative NT-proBNP. This has to be
hecked in other groups of hypertensive patients with a dif-
erent prevalence of LVH. It also has to be conﬁrmed with
agnetic resonance imaging determination of LVH, which
ould be more relevant. Taken as a whole, the present
esults open the way for a new strategy of risk stratiﬁcation
n hypertension.
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